4.8 Article

Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk

期刊

HEPATOLOGY
卷 53, 期 5, 页码 1696-1707

出版社

WILEY
DOI: 10.1002/hep.24230

关键词

-

资金

  1. European Union [222878]
  2. Telethon
  3. PERSIST
  4. Bayer-Schering Hemophilia
  5. Fund for Scientific Research (FWO & FWO-Wetenschappelijke Onderzoeksgemeenschap)
  6. Geconcentreerde Onderzoek Acties'' GOA-EPIGEN (Free University of Brussels)
  7. European Hematology Association (EHA) [2010/21]
  8. Association Francaise contre les Myopathies (AFM)
  9. Stichting tegen Kanker (STK)

向作者/读者索取更多资源

Lentiviral vectors are attractive tools for liver-directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects. However, the use of integrating vectors may raise some concerns about the potential risk of insertional mutagenesis. Here we investigated liver gene transfer by integrase-defective lentiviral vectors (IDLVs) containing an inactivating mutation in the integrase (D64V). Hepatocyte-targeted expression using IDLVs resulted in the sustained and robust induction of immune tolerance to both intracellular and secreted proteins, despite the reduced transgene expression levels in comparison with their integrase-competent vector counterparts. IDLV-mediated and hepatocyte-targeted coagulation factor IX (FIX) expression prevented the induction of neutralizing antibodies to FIX even after antigen rechallenge in hemophilia B mice and accounted for relatively prolonged therapeutic FIX expression levels. Upon the delivery of intracellular model antigens, hepatocyte-targeted IDLVs induced transgene-specific regulatory T cells that contributed to the observed immune tolerance. Deep sequencing of IDLV-transduced livers showed only rare genomic integrations that had no preference for gene coding regions and occurred mostly by a mechanism inconsistent with residual integrase activity. Conclusion: IDLVs provide an attractive platform for the tolerogenic expression of intracellular or secreted proteins in the liver with a substantially reduced risk of insertional mutagenesis. (HEPATOLOGY 2011;53:1696-1707)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, General & Internal

In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges

Alessio Cantore, Alessandro Fraldi, Vasco Meneghini, Angela Gritti

Summary: In vivo genetic engineering is a promising treatment method for various diseases, with viral vector-mediated gene transfer and genome/epigenome editing being the main approaches. This review explores the advanced in vivo gene therapies available and in development, and discusses the challenges and potential solutions, focusing on the nervous system and liver as examples.

FRONTIERS IN MEDICINE (2022)

Article Multidisciplinary Sciences

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates

Michela Milani, Cesare Canepari, Tongyao Liu, Mauro Biffi, Fabio Russo, Tiziana Plati, Rosalia Curto, Susannah Patarroyo-White, Douglas Drager, Ilaria Visigalli, Chiara Brombin, Paola Albertini, Antonia Follenzi, Eduard Ayuso, Christian Mueller, Andrea Annoni, Luigi Naldini, Alessio Cantore

Summary: Liver gene therapy using lentiviral vectors that integrate into the host cell genome has shown efficient liver gene transfer in mice, dogs, and non-human primates. In this study, we compared engineered coagulation factor VIII transgenes and found that codon-usage optimization and inclusion of an unstructured XTEN peptide significantly increased factor VIII expression in mice and non-human primates. Stable and long-term normal or above-normal factor VIII activity was achieved in hemophilia A mouse models. This research opens up new possibilities for treating hemophilia A using lentiviral gene therapy.

NATURE COMMUNICATIONS (2022)

Article Medicine, Research & Experimental

Editing T cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development

Fabio Russo, Eliana Ruggiero, Rosalia Curto, Laura Passeri, Francesca Sanvito, Ileana Bortolomai, Anna Villa, Silvia Gregori, Andrea Annoni

Summary: The study developed a gene transfer approach to modify the T cell repertoire in thymic epithelial cells, correcting the autoimmune response in type 1 diabetes. The strategy involved intrathymic injection of a lentiviral vector to achieve stable transgene expression in thymic epithelial cells, leading to successful correction of the disease in mice models.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Article Biotechnology & Applied Microbiology

Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy

Jaitip Tipanee, Ermira Samara-Kuko, Thierry Gevaert, Marinee K. Chuah, Thierry VandenDriessche

Summary: This study developed a non-viral platform based on Sleeping Beauty transposons and minicircles for genetic modification, allowing efficient expression of CD19-28z.CAR and inactivation of allogeneic TCRs using CRISPR-Cas9. The resulting CAR T cells showed anti-tumor activity against CD19+ tumor cells and induced complete tumor remission in a mouse model, while minimizing TCR alloreactivity and GvHD. This non-viral approach provides an alternative method for generating next-generation CD19-specific CAR T cells, reducing GvHD risk and manufacturing constraints associated with viral vectors.

MOLECULAR THERAPY (2022)

Editorial Material Biotechnology & Applied Microbiology

First conditional marketing authorization approval in the European Union for hemophilia A gene therapy

Thierry VandenDriessche, Steven W. Pipe, Glenn F. Pierce, Radoslaw Kaczmarek

MOLECULAR THERAPY (2022)

Editorial Material Biotechnology & Applied Microbiology

Hemophilia A gene therapy: Lost in translation

Thierry VandenDriessche, Marinee K. Chuah

MOLECULAR THERAPY (2022)

Review Biotechnology & Applied Microbiology

Hemophilia Gene Therapy: The End of the Beginning?

Dries De Wolf, Kshitiz Singh, Marinee K. Chuah, Thierry Vandendriessche

Summary: Extensive preclinical research has led to the recent regulatory approval of gene therapy products for hemophilia. Roctavian and Hemgenix have shown significant efficacy and safety in clinical trials, resulting in increased levels of clotting factors and reduced bleeding episodes for patients. However, there is variability in patient response and short-term liver inflammation was observed. Longer follow-up studies are needed to determine if lifelong expression of clotting factors can be achieved. Next-generation gene editing technologies offer new prospects for a sustained cure for hemophilia.

HUMAN GENE THERAPY (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Liver directed lentiviral gene therapy provides long term phenotypic correction of methylmalonic acidemia in a mouse model

E. Barbon, C. Negri, A. Raimondi, A. Fabiano, F. Russo, G. la Marca, A. Cantore

HUMAN GENE THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Low-density lipoprotein (LDL) receptor liver gene transfer with lentiviral vectors achieves full normalization of LDL cholesterol and protection from atherosclerosis in a mouse model of familial hypercholesterolemia

C. Canepari, M. Milani, F. Russo, F. Starinieri, R. Norata, M. Rocchi, M. Biffi, A. Fabiano, F. Sanvito, A. Cantore

HUMAN GENE THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Lentiviral Vector Mediated In Vivo Gene Transfer into Liver Organoid Forming Cells in Mice and Non-Human Primates

Michela Milani, Francesco Starinieri, Stefano Beretta, Tiziana Plati, Anna Fabiano, Cesare Canepari, Luigi Aloia, Fabio Russo, Mauro Biffi, Ivan Merelli, Meritxell Huch, Luigi Naldini, Alessio Cantore

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Direct Cross Species Comparison of Lentiviral Vector Hepatocyte Transduction Efficiency

Susannah Patarroyo-White, Samantha Wilder, Douglas Drager, Alessio Cantore, Michela Milani, Andrea Annoni, Mauro Biffi, Luigi Naldini, Dinesh Bangari, Mostafa Kabiri, Michelle Potter, Tongyao Liu, Christian Mueller

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Investigating Liver Tissue Dynamics to Improve In Vivo Gene Therapy with Lentiviral Vectors

Francesco Starinieri, Michela Milani, Cesare Canepari, Chiara Simoni, Anna Fabiano, Tiziana Plati, Mauro Biffi, Fabio Russo, Eugenia Cammarota, Alessio Cantore

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Liver Directed Lentiviral Gene Therapy Ameliorates the Phenotype of Progressive Familiar Intrahepatic Cholestasis Type 2 in a Mouse Model

Elena Barbon, Camilla Negri, Chiara Simoni, Anna Fabiano, Fabio Russo, Alessio Cantore

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Low-Density Lipoprotein (LDL) Receptor Liver Gene Transfer with Lentiviral Vectors Normalizes Circulating LDL Cholesterol in a Mouse Model of Familial Hypercholesterolemia

Cesare Canepari, Michela Milani, Fabio Russo, Mauro Biffi, Anna Fabiano, Andrea Annoni, Alessio Cantore

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

In Vivo Generation of CAR T Cells in Presence of Human Myeloid Cells

Naphang Ho, Shiwani Agarwal, Michela Milani, Alessio Cantore, Christian Buchholz, Frederic Thalheimer

MOLECULAR THERAPY (2022)

暂无数据